APX001

DRUG4 trials

Sponsors

Basilea Pharmaceutica

Conditions

Candida InfectionCandidemiaFungal InfectionInvasive CandidiasesInvasive Fungal Infections

Phase 1

A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001

CompletedNCT04166669

Basilea PharmaceuticaFungal Infection

Start: 2019-11-12End: 2020-03-03Updated: 2024-05-17

A Bioequivalence Study of APX001 High-load and Low-load Tablets

CompletedNCT05491733

Basilea PharmaceuticaInvasive Fungal Infections

Start: 2021-03-02End: 2021-06-23Updated: 2024-07-11

Phase 2

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

CompletedNCT03604705

Basilea PharmaceuticaCandidemia

Start: 2018-10-03End: 2020-07-02Updated: 2025-09-16

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris

CompletedNCT04148287

Basilea PharmaceuticaCandida Infection, Candidemia, Invasive Candidiases

Start: 2019-12-13End: 2020-12-31Updated: 2025-09-16

Related Papers

Phase 1 drug-drug interaction study to assess the effect of CYP3A4 inhibition and pan-CYP induction on the pharmacokinetics and safety of fosmanogepix in healthy participants

Antimicrobial Agents and Chemotherapy2024-05-175 citations

2043. <i>In Vitro</i> Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020-2021) Stratified by Infection Type

Open Forum Infectious Diseases2022-12-012 citations

Reason and reality—identifying barriers to patient enrolment for clinical trials in invasive candidiasis

Journal of Antimicrobial Chemotherapy2022-10-104 citations